Article
Oral mucosal keratinocytes have a high mitotic rate and are, like cancer cells, targets of RT and cancer cytotoxic CTX agents. Mucosal damage is one of the most common adverse effects of CTX and of RT to the head and neck, with a prevalence ranging from 10–100%. Cancer therapy thus produces collateral damage. Mucositis is the result of a complex series of biological events that ultimately lead to ulceration and is often a dose-limiting toxicity. Thus, while other toxicities of cancer therapy may be declining following, for example, the introduction of Intensity Modulated Radiation Therapy (IMRT), mucositis remains an area of concern to both patients and clinicians. Even newer agents may produce oral ulceration or enhance toxicity of RT and of CTX. These include:
Radiotherapy-induced mucositis
RT is most often administered in small fractions over several weeks and to a localized area. Radiation-induced mucositis is invariable within the radiated field of mucosa and typically begins at cumulative doses of about 15 Gy (ie after around 10 days) and reaches full severity at 30 Gy, persisting for weeks or months (Figure 1). Tissues such as the soft palate, and the lateral borders and ventral surface of the tongue and floor of the mouth, which have a good vascular supply or a higher cell turnover rate, are more susceptible to radiation mucositis. Risk factors for radiation mucositis, apart from the radiation dose and fractionation include:
Chemotherapy-induced mucositis
Chemotherapy is administered over a short time, so the injury to mucosae tends to be acute and affects the whole gastrointestinal tract. Most patients on high-dose CTX develop severe oral mucositis which usually appears within 4–7 days after initiation of treatment and peaks within 2 weeks.
Risk factors for CTX mucositis include:
Pathobiology
The damage induced by CTX is a complex phenomenon that affects both epithelium and lamina propria. There are several stages in mucositis:
The oral microflora is considered to play only a secondary role in the pathogenesis of mucositis.
Clinical features
Oral mucositis is defined as inflammation of the mucosa resulting from cancer therapy and typically presents as erythema, ulceration, swelling and atrophy. Mucositis may be exacerbated by local factors, such as trauma from teeth, or microbial colonization. Since chemotherapy-induced damage affects the entire alimentary tract mucosae, terms such as alimentary mucositis and mucosal barrier injury are also then used.
The effect of mucositis on quality of life
Many patients report oral mucositis as the most debilitating and troublesome adverse effect of cancer therapy, and that opioid analgesics did not always adequately relieve pain, but instead led to other issues such as dry mouth and constipation. Mucositis is also associated with poorer treatment outcomes and increased financial burdens, a longer hospital stay, and an increased use of narcotics and nutritional support. In some patients, mainly those undergoing myeloablative haematopoietic stem cell transplant (HSCT, or bone marrow transplant), mucositis predisposes to fever and infections, and occasionally mortality.
Diagnosis
Lesions in the cancer patient that can complicate the diagnosis include:
Quantification
A number of instruments is available to evaluate the observable, subjective and functional dimensions of oral mucositis (eg World Health Organization, National Cancer Institute Common Terminology Criteria for Adverse Events, or Eilers' Oral Assessment Guide for a more comprehensive oral assessment).
Nevertheless, the incidence of mucositis is widely under-reported. Clinician-based scorings of toxicities often fail to coincide with targeted mucosal evaluation or patients' reporting of symptoms. For example, while incidence of oral mucositis reported by oncologists was about 15% in patients receiving CTX for colorectal cancer, over 70% of the patients being treated reported significant mouth or throat soreness.
Management
Unfortunately, there are few randomized controlled studies and the available prophylactic and therapeutic strategies are limited. Topical anaesthetic (Viscous lidocaine®) coating agents may be of some value, but the pain usually requires systemic analgesics for relief. Since infections may be associated, appropriate diagnosis and antimicrobial agents must be considered. Fungal or bacterial infections may be seen in either CTX or RT-induced mucositis but viral infections seem to be rare in patients with RT-induced mucositis.
Interventions which have some proven success include:
There are several clinical practice guidelines on mucositis available (recent ones shown in Tables 1 and 2).
Guidelines from | References |
---|---|
COCHRANE (2006, 2007) | Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. |
MASCC/ISOO(2004, 2007) | Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, (2004, 2007) Epstein JB, et al.: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; |
ASCO (2008) | Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical Oncology 2008 Clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27(1): 127–145. |
NCCN (2008) | Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, Eilers JG, et al. |
ESMO (2010) | Peterson DE, Bensadoun RJ, Roila F; ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21(Suppl 5): v261–265. |
Basic oral care and good clinical practices
|
There is limited evidence for the efficacy of a supersaturated calcium phosphate rinse for the prevention and treatment of mucositis.
New agents being trialed for the amelioration of mucositis include supplements (eg glutamine, zinc sulphate), enzymes involved in the detoxification of reactive oxygen species (eg glutathione-S-transferase) and antimicrobial peptides. In addition, epigenetic approaches aimed at modifying overexpression of pro-inflammatory cytokines seem promising.